Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases

scientific article

Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1002/MED.20207
P698PubMed publication ID20577972
P5875ResearchGate publication ID44799970

P50authorAna MartínezQ30506374
Carmen GilQ45286654
Daniel I PérezQ56250319
P2860cites workThe blood-brain barrier: bottleneck in brain drug developmentQ22336985
Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzymeQ24291728
Modeling of a human circadian mutation yields insights into clock regulation by PER2Q24292897
Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer diseaseQ24308731
The protein kinase complement of the human genomeQ24324497
Dopamine covalently modifies and functionally inactivates parkinQ24338423
The effects of connexin phosphorylation on gap junctional communicationQ24603834
Setting clock speed in mammals: the CK1 epsilon tau mutation in mice accelerates circadian pacemakers by selectively destabilizing PERIOD proteinsQ24629727
The selectivity of protein kinase inhibitors: a further updateQ24654622
Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituentQ27621242
Crystal structure of a conformation-selective casein kinase-1 inhibitorQ27622090
The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2Q27625243
Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazoleQ27635437
Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insightQ27639922
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA)Q27641451
The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small moleculesQ27649904
Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2Q27655439
Casein kinase I-like protein kinases encoded by YCK1 and YCK2 are required for yeast morphogenesisQ27932715
Constitutive phosphorylation of the Parkinson's disease associated alpha-synucleinQ28141645
Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formationQ28188133
Casein kinase I: another cog in the circadian clockworksQ28209277
The casein kinase 1 family: participation in multiple cellular processes in eukaryotesQ28235956
Synaptic transmission block by presynaptic injection of oligomeric amyloid betaQ28238942
Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid betaQ28239322
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective functionQ28258212
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosisQ28261784
Regulation of Alzheimer's disease amyloid-beta formation by casein kinase IQ28577875
An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditionsQ28578516
Polyhalogenobenzimidazoles: synthesis and their inhibitory activity against casein kinasesQ28581363
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismQ29547302
Targeting cancer with small molecule kinase inhibitorsQ29547395
Protein kinases--the major drug targets of the twenty-first century?Q29615339
One-thousand-and-one substrates of protein kinase CK2?Q29615345
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosisQ29615597
Parkinson's diseaseQ29616302
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activityQ30448692
Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum.Q30913371
Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo studyQ31117999
Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).Q33207638
p53-dependent inhibition of mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory subunit of protein kinase CK2.Q33245656
Expanding the chemical diversity of CK2 inhibitors.Q33344802
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivoQ33346339
The selectivity of inhibitors of protein kinase CK2: an updateQ33347545
Purification of casein kinase I and isolation of cDNAs encoding multiple casein kinase I-like enzymesQ33451141
Targeting protein kinases in central nervous system disordersQ33671660
Casein kinase 2 as a potentially important enzyme in the nervous systemQ33829605
Identification of inhibitory autophosphorylation sites in casein kinase I epsilonQ33878515
Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synucleinQ34091623
Role of COOH-terminal Phosphorylation in the Regulation of Casein Kinase IδQ34304545
p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugsQ34444295
A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's diseaseQ34505264
Toward the rational design of protein kinase casein kinase-2 inhibitorsQ34792890
A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine.Q34892958
Protein kinase CK2: structure, regulation and role in cellular decisions of life and deathQ34978734
Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock periodQ34982171
MAPKs: new targets for neurodegenerationQ35095136
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trialsQ35155745
Protein kinase CK2 in health and disease: CK2: a key player in cancer biologyQ35270830
Rho kinase, a promising drug target for neurological disordersQ36111908
The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer developmentQ36269124
Features and potentials of ATP-site directed CK2 inhibitorsQ36273845
Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2.Q36276160
CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signalingQ36397808
Tau therapeutic strategies for the treatment of Alzheimer's diseaseQ36483103
Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2').Q43601491
Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivativesQ43688171
Protein kinase CK2: a newcomer in the 'druggable kinome'.Q44016530
Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1.Q44316862
Characterization of (-)-matairesinol as a potent inhibitor of casein kinase I in vitroQ44337455
Aberrant casein kinase II in Alzheimer's diseaseQ44378382
Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources.Q44466447
Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput dockingQ44474542
Casein kinase II is associated with neurofibrillary tangles but is not an intrinsic component of paired helical filamentsQ44664318
2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.Q45052212
Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazoleQ45164317
Inclining the purine base binding plane in protein kinase CK2 by exchanging the flanking side-chains generates a preference for ATP as a cosubstrate.Q45290258
Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).Q45713586
Identification of casein kinase-1 phosphorylation sites on TDP-43.Q46088509
Autophosphorylation of carboxy-terminal residues inhibits the activity of protein kinase CK1alphaQ46179780
Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screeningQ46361622
Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.Q46478098
Protein kinase CK2 modulates synaptic plasticity by modification of synaptic NMDA receptors in the hippocampusQ46593528
Physiological role for casein kinase 1 in glutamatergic synaptic transmission.Q46598656
Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective functionQ46797053
Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivoQ46802179
Casein kinase I transduces Wnt signalsQ47069139
Neurotrophin-induced activation of casein kinase 2 in rat hippocampal slicesQ47734681
Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesisQ48139089
Different expression patterns of CK2 subunits in the brains of experimental animals and patients with transmissible spongiform encephalopathiesQ48437741
Identifying interaction motifs in CK2beta--a ubiquitous kinase regulatory subunitQ48545932
Casein kinase-1 isoforms differentially associate with neurofibrillary and granulovacuolar degeneration lesionsQ48606594
Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitroQ48895043
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.Q48965240
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.Q51028667
Inhibition of casein kinase I epsilon/delta produces phase shifts in the circadian rhythms of Cynomolgus monkeys.Q51773887
Amyloid beta-protein stimulates casein kinase I and casein kinase II activities.Q52221605
Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.Q52575181
Identification of chemical inhibitors of protein-kinase CK2 subunit interaction.Q52587478
Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain.Q53234938
Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases.Q53236807
Glycogen synthase kinase 3 phosphorylation of different residues in the presence of different factors: analysis on tau protein.Q53856938
Synthesis and kinase inhibitory activity of novel substituted indigoids.Q54727713
Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism.Q55042756
Protein kinase CK2 links extracellular growth factor signaling with the control of p27Kip1 stability in the heartQ56973092
Mass Spectrometry Analysis of a Protein Kinase CK2β Subunit Interactome Isolated from Mouse Brain by Affinity ChromatographyQ58037526
Circadian rhythms in the CNS and peripheral clock disorders: human sleep disorders and clock genesQ36735272
Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrestQ36787138
CK2beta gene silencing increases cell susceptibility to influenza A virus infection resulting in accelerated virus entry and higher viral protein contentQ36808656
JNK signalling: a possible target to prevent neurodegeneration.Q36855703
Hemoglobin neurotoxicity is attenuated by inhibitors of the protein kinase CK2 independent of heme oxygenase activityQ36915740
Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.Q36968720
Tumorigenesis and neurodegeneration: two sides of the same coin?Q37214823
A structural insight into CK2 inhibitionQ37216422
Protein kinase CK2 in human diseases.Q37239690
Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disordersQ37249765
ATP-noncompetitive inhibitors of CDK-cyclin complexes.Q37336692
Casein Kinase I epsilon positively regulates the Akt pathway in breast cancer cell linesQ37390974
New protein kinase CK2 inhibitors: jumping out of the catalytic box.Q37402052
Protein kinase inhibitors: contributions from structure to clinical compoundsQ37417742
Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a reviewQ37418238
Protein kinase CK2 in health and disease: Protein kinase CK2: from structures to insights.Q37456255
Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interactionQ38299025
The regulatory beta subunit of protein kinase CK2 mediates formation of tetrameric CK2 complexesQ38315495
3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.Q39826704
Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1.Q39951176
Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.Q40082517
D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a.Q40098388
Development and exploitation of CK2 inhibitorsQ40342605
Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapyQ40503541
Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubulesQ40592760
RING finger 1 mutations in Parkin produce altered localization of the proteinQ40629977
Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotypeQ40817463
Anticancer alkaloid lamellarins inhibit protein kinasesQ41905449
Casein kinase II contributes to the synergistic effects of BMP7 and BDNF on Smad 1/5/8 phosphorylation in septal neurons under hypoglycemic stressQ41912514
Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2.Q43277656
P433issue6
P921main subjectneurodegenerationQ1755122
PF-4800567Q7119049
P304page(s)924-954
P577publication date2010-06-23
P1433published inMedicinal Research ReviewsQ2436033
P1476titleProtein kinases CK1 and CK2 as new targets for neurodegenerative diseases
P478volume31

Reverse relations

cites work (P2860)
Q526566201-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders.
Q276772502-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1δ/ε
Q64788264A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition
Q33559650Alleviation of behavioral hypersensitivity in mouse models of inflammatory pain with two structurally different casein kinase 1 (CK1) inhibitors
Q52654990Atlas stumbled: kinesin light chain-1 variant E triggers a vicious cycle of axonal transport disruption and amyloid-β generation in Alzheimer's disease.
Q33736687Bioactive marine drugs and marine biomaterials for brain diseases
Q60897585Biological and Pharmacological Characterization of Benzothiazole-Based CK-1δ Inhibitors in Models of Parkinson's Disease
Q38828117CK1δ activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylation
Q42204673CK1δ in lymphoma: gene expression and mutation analyses and validation of CK1δ kinase activity for therapeutic application
Q54109929CK2 Phosphorylating I2PP2A/SET Mediates Tau Pathology and Cognitive Impairment.
Q39076762CK2-An Emerging Target for Neurological and Psychiatric Disorders
Q38211598Casein kinase: the triple meaning of a misnomer
Q38632634Casein kinases as potential therapeutic targets
Q34127839Circadian gene variants in cancer.
Q36798054Crosstalk between casein kinase II and Ste20-related kinase Nak1.
Q93166659Discovering New Casein Kinase 1d Inhibitors with an Innovative Molecular Dynamics Enabled Virtual Screening Workflow
Q34891066Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants
Q42481944Effects of CK2 inhibition in cultured fibroblasts from Type 1 Diabetic patients with or without nephropathy
Q38303007Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients
Q28482403Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth
Q40189553Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis
Q39357662FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration
Q26865707Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder
Q34591684Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease
Q27930417Hrr25/CK1δ-directed release of Ltv1 from pre-40S ribosomes is necessary for ribosome assembly and cell growth
Q30454128Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors
Q36433202Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology.
Q36063680Interaction of CK1δ with γTuSC ensures proper microtubule assembly and spindle positioning
Q36268711Novel group-based QSAR and combinatorial design of CK-1δ inhibitors as neuroprotective agents
Q98563342Ozone: a natural bioactive molecule with antioxidant property as potential new strategy in aging and in neurodegenerative disorders
Q33797449Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis
Q30574827Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis
Q37247661Protein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development.
Q38815398Protein kinase CK2 regulates metal toxicity in neuronal cells
Q90378129Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients
Q34333403SNP-PRAGE: SNP-based parametric robust analysis of gene set enrichment
Q47884524Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents.
Q27682893Structure of the kinase domain of Gilgamesh fromDrosophila melanogaster
Q36855812Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia.
Q21129297The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis
Q54978506The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms.
Q28077409The New Role for an Old Kinase: Protein Kinase CK2 Regulates Metal Ion Transport
Q36237271The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation
Q28293759The casein kinase 2-nrf1 axis controls the clearance of ubiquitinated proteins by regulating proteasome gene expression
Q91866908Therapeutic Potential of the Hsp90/Cdc37 Interaction in Neurodegenerative Diseases
Q37374036Transcriptome analysis of HIV-infected peripheral blood monocytes: gene transcripts and networks associated with neurocognitive functioning
Q35526322Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2.

Search more.